Global CEO Grouping Lays Out Japan, Wider Priorities Ahead Of G7 Meeting
UHC, Access, Pricing In Spotlight
The Biopharmaceutical CEO Roundtable has added a chorus of C-suite voices to ongoing calls for Japan reform discussions, while also flagging key global health agenda items for the upcoming G7 meeting in the country.
You may also be interested in...
As the COVID-19 graph trends upward in countries like India, preparing for future pandemics is high on the agenda of intergovernmental forum G20. Digital healthcare and governance tools, One Health approach and tackling AMR emerged as focus areas at the recent meeting of its Health Working Group
Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.
In this week's podcast edition of Five Must-Know Things: Bayer takes strategic steps to cut debt; AbbVie confirms internal appointment as CEO; another RIPK1 setback for Denali/Sanofi; new biotech reality in China; and ex-Daiichi Sankyo CEO shares insights into tough decisions.